Alzheimer's Disease Overview

Principles

Definition

Alzheimer's disease is a significant and multidisciplinary field of biomedical research and clinical study focused on the complex etiology, neuropathological processes, diagnosis, treatment, and prevention of this specific, progressive neurodegenerative disorder. This academic domain encompasses investigations across molecular biology, genetics, cellular pathology, neuroimaging, cognitive science, and clinical trials, aiming to understand the disease's mechanisms and develop effective interventions to alleviate its devastating impact.

Ontological type

Molecular Pathogenesis

Therapeutic Approaches

Diagnostic Strategies

Key developments

Key Figures

Mechanistic Hypothesis Formation era

Konrad Beyreuther [1] was affiliated with Johns Hopkins University [3] and University of California, San Diego [4] during this era. His key contributions included identifying the precursor of Alzheimer's disease A4 amyloid protein [6] and describing its resemblance to a cell-surface receptor [6], together with elucidations of its biogenesis and localization [7], advances that were crucial for establishing mechanistic links between amyloid pathology and cognitive decline in this era. Colin L. Masters [2] was affiliated with Johns Hopkins University [3] and Albert Einstein College of Medicine [5] in this period. His key contributions centered on the identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein [7], and the complementary findings on precursor identification and localization described in [6], which provided crucial mechanistic insights that informed the era's mechanistic hypothesis linking amyloid biology to cortical degeneration and cognitive decline.

Amyloid-Centric Model era

Rudolph E. Tanzi [1], affiliated with Rockefeller University [3] and Harvard University [4] during the Amyloid-Centric Model era (1994–2009), helped anchor the focus on amyloid pathways. Tanzi [1] contributed key findings evident in the 1996 secreted amyloid beta paper [7] and in the 2001 copper-zinc chelator study [8], illustrating how familial APP mutations increase secreted Aβ and how chelation rapidly lowers Aβ, thereby reinforcing the centrality of Aβ dynamics in this era. Mark P. Mattson [2], affiliated with Johns Hopkins University [5] and the University of Pennsylvania [6], advanced the era with the 2003 triple-transgenic model of Alzheimer's disease with plaques and tangles [9], providing an in vivo system that integrates key pathological features. This model, championed by Mattson [2], enabled preclinical therapeutic testing and mechanistic dissection, thereby shaping trial design and biomarker priorities within the amyloid-centric framework.

Biomarker-Driven Biology era

María C. Carrillo [1], affiliated with Johns Hopkins University [3] and the University of California, San Diego [4] during this era, helped shape biomarker-driven definitions of Alzheimer's disease. Her key contributions in this era include guiding the 2011 dementia-diagnosis recommendations [7], defining the preclinical stages of Alzheimer's disease [8], and contributing to the 2012 guidelines for the neuropathologic assessment [9], which established biomarker-guided staging and informed trial design. Clifford R. Jack [2], connected with the University Memory and Aging Center [5] and Harvard University [6] during this epoch, helped translate these biomarker-focused concepts into universal staging frameworks. In turn, the two 2011 guideline papers [7][8] advanced the practical adoption of amyloid and other biomarker criteria to guide diagnosis and trial enrollment, a cornerstone of biomarker-driven biology in this era.